Pemetreksed

Iz Wikipedije, slobodne enciklopedije
Idi na navigaciju Idi na pretragu
Pemetreksed
Klinički podaci
AHFS/Drugs.com Monografija
Identifikatori
CAS broj 150399-23-8
ATC kod L01BA04
PubChem[1][2] 60843
DrugBank DB00642
ChemSpider[3] 54830
ChEMBL[4] CHEMBL225072 YesY
Hemijski podaci
Formula C20H21N5O6 
Mol. masa 427,411
SMILES eMolekuli & PubHem
Farmakokinetički podaci
Poluvreme eliminacije 3,5 h
Farmakoinformacioni podaci
Trudnoća ?
Pravni status
Način primene Intravenozno

Pemetreksed (prodajni naziv Alimta) je hemoterapijski lek koji proizvodi i prodaje preduzeće Eli Lilly and Company. Njegove indikacije su tretman raka pleuralnog mezotelioma i makrocelularnog karcinoma pluća.

Pemetreksed je organsko jedinjenje, koje sadrži 20 atoma ugljenika i ima molekulsku masu od 427,411 Da.[5][6][7][8][9][10]

Mehanizam dejstva[uredi - уреди | uredi izvor]

Pemetreksed je hemijski sličan folnoj kiselina i pripada klasi hemoterapijskih lekova zvanih folatni antimetaboliti. On deluje putem inhibiranja tri enzima koji se koriste u sintezi purina i pirimidinatimidilatna sintaza (TS), dihidrofolatna reduktaza (DHFR), i glicinamid ribonukleotidna formiltransferaza[11][12] (GARFT). Putem inhibiranja formiranja prekursora purinskih i pirimidinskih nukleotida, pemetreksed sprečava formiranje DNK i RNK, koje su neophodne za rast i opstanak normalnih i kanceroznih ćelija.

Osobine[uredi - уреди | uredi izvor]

Osobina Vrednost
Broj akceptora vodonika 9
Broj donora vodonika 6
Broj rotacionih veza 9
Particioni koeficijent[13] (ALogP) 1,1
Rastvorljivost[14] (logS, log(mol/L)) -4,5
Polarna površina[15] (PSA, Å2) 187,0

Reference[uredi - уреди | uredi izvor]

  1. Li Q, Cheng T, Wang Y, Bryant SH (2010). "PubChem as a public resource for drug discovery.". Drug Discov Today 15 (23-24): 1052–7. PMID 20970519. doi:10.1016/j.drudis.2010.10.003.  edit
  2. Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). "Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities". Annual Reports in Computational Chemistry 4: 217–241. doi:10.1016/S1574-1400(08)00012-1. 
  3. Hettne KM, Williams AJ, van Mulligen EM, Kleinjans J, Tkachenko V, Kors JA. (2010). "Automatic vs. manual curation of a multi-source chemical dictionary: the impact on text mining". J Cheminform 2 (1): 3. PMID 20331846. doi:10.1186/1758-2946-2-3.  edit
  4. Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, Hersey A, Light Y, McGlinchey S, Michalovich D, Al-Lazikani B, Overington JP. (2012). "ChEMBL: a large-scale bioactivity database for drug discovery". Nucleic Acids Res 40 (Database issue): D1100–7. PMID 21948594. doi:10.1093/nar/gkr777.  edit
  5. Rollins KD, Lindley C: Pemetrexed: a multitargeted antifolate. Clin Ther. 2005 Sep;27(9):1343-82. PMID 16291410
  6. Lansiaux A, Lokiec F: [Pemetrexed: from preclinic to clinic] Bull Cancer. 2007;94 Spec No Actualites:S134-8. PMID 17845983
  7. Fuld AD, Dragnev KH, Rigas JR: Pemetrexed in advanced non-small-cell lung cancer. Expert Opin Pharmacother. 2010 Jun;11(8):1387-402. PMID 20446853
  8. Adjei AA: Pemetrexed (Alimta): a novel multitargeted antifolate agent. Expert Rev Anticancer Ther. 2003 Apr;3(2):145-56. PMID 12722874
  9. Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS (2011). "DrugBank 3.0: a comprehensive resource for omics research on drugs". Nucleic Acids Res. 39 (Database issue): D1035–41. PMC 3013709. PMID 21059682. doi:10.1093/nar/gkq1126.  edit
  10. David S. Wishart, Craig Knox, An Chi Guo, Dean Cheng, Savita Shrivastava, Dan Tzur, Bijaya Gautam, and Murtaza Hassanali (2008). "DrugBank: a knowledgebase for drugs, drug actions and drug targets". Nucleic acids research 36 (Database issue): D901–6. PMC 2238889. PMID 18048412. doi:10.1093/nar/gkm958.  edit
  11. McLeod, Howard L.; James Cassidy, Robert H. Powrie, David G. Priest, Mark A. Zorbas, Timothy W. Synold, Stephen Shibata, Darcy Spicer, Donald Bissett, Yazdi K. Pithavala, Mary A. Collier, Linda J. Paradiso, John D. Roberts (Jul 2000). "Pharmacokinetic and Pharmacodynamic Evaluation of the Glycinamide Ribonucleotide Formyltransferase Inhibitor AG2034". Clinical Cancer Research 6 (7): 2677–84. PMID 10914709.  Check date values in: |date= (help)
  12. Avendano, Carmen; Menendez, J. Carlos (April 2008). Medicinal Chemistry of Anticancer Drugs. Amsterdam: Elsevier. str. 37. ISBN 0-444-52824-5. http://books.google.com/?id=GjhXyqB5iLcC. 
  13. Ghose, A.K., Viswanadhan V.N., and Wendoloski, J.J. (1998). "Prediction of Hydrophobic (Lipophilic) Properties of Small Organic Molecules Using Fragment Methods: An Analysis of AlogP and CLogP Methods". J. Phys. Chem. A 102: 3762–3772. doi:10.1021/jp980230o. 
  14. Tetko IV, Tanchuk VY, Kasheva TN, Villa AE. (2001). "Estimation of Aqueous Solubility of Chemical Compounds Using E-State Indices". Chem Inf. Comput. Sci. 41: 1488–1493. PMID 11749573. doi:10.1021/ci000392t.  edit
  15. Ertl P., Rohde B., Selzer P. (2000). "Fast calculation of molecular polar surface area as a sum of fragment based contributions and its application to the prediction of drug transport properties". J. Med. Chem. 43: 3714–3717. PMID 11020286. doi:10.1021/jm000942e.  edit

Literatura[uredi - уреди | uredi izvor]

Spoljašnje veze[uredi - уреди | uredi izvor]

Star of life.svg Molimo Vas, obratite pažnju na važno upozorenje u vezi tema o zdravlju (medicini).